Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Type 2 diabetes: PAD and diabetic foot syndrome
Prevention is better than cure – don’t miss the risk foot
- Prostate cancer
High-resolution ultrasound could diagnose prostate cancer faster
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Lung carcinoma – Pancoast tumor
- Deep vein thrombosis
Outpatient or inpatient treatment?
- From symptom to diagnosis